Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

Summary

This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. The primary hypothesis is that at least 1 dose of tulisokibart is superior to placebo with respect to the proportion of participants achieving a 50% reduction in Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 16 (ie, at end of double-blind treatment).

Timeline

Start

2025-06-09

Primary completion

2026-11-16

Completion

2029-01-22

Outcome

Met primary endpoint

release “The study met its primary endpoint of Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at week 16” msd.com ↗

Drugs

Indications